Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Aug 22;8(9):80.
doi: 10.1038/s41408-018-0117-0.

Survival After Blinatumomab Treatment in Pediatric Patients With Relapsed/Refractory B-cell Precursor Acute Lymphoblastic Leukemia

Affiliations
Free PMC article

Survival After Blinatumomab Treatment in Pediatric Patients With Relapsed/Refractory B-cell Precursor Acute Lymphoblastic Leukemia

Lia Gore et al. Blood Cancer J. .
Free PMC article

Conflict of interest statement

L. Gore is a stockholder of Amgen, Sanofi, Celgene, Clovis Oncology and Ignyta, has received consulting and travel honoraria from Bristol Myers-Squibb, Celgene, Genentech/Roche, Amgen, Novartis, and ProEd Communications, and holds a patent for diagnostic discovery and treatment response methodology tools in the use of MR spectroscopy for leukemia. F. Locatelli has received honoraria from Amgen and Miltenyi Biotec, consulting fees from Amgen, research funding from Neovii Biotech, and travel support from Medac. G. Zugmaier is an employee and stockholder of Amgen, and holds patents with Amgen and Micromet. R. Handgretinger holds a patent with Miltenyi Biotec. M.M. O’Brien has received consulting fees from Amgen, research funding from Amgen, Seattle Genetics, Epizyme, Celgene, and BTG and travel support from Amgen, Celgene, and AROG Pharmaceuticals. P. Bader has received consulting fees from Amgen and Novartis, and research funding from Medac, Neovii Biotech, and RIEMSER; and is a patent holder with Medac. D. Bhojwani has received travel support from Amgen. C.A. Tuglus is an employee and stockholder of Amgen. A. von Stackelberg has received honoraria from Amgen, ERYTECH Pharma, Novartis, Roche, and Jazz Pharmaceuticals, consulting fees from Amgen, ERYTECH Pharma, Novartis, and Roche, and travel support from Amgen and ERYTECH Pharma, and has been a member of a speakers’ bureau for Amgen. P.-G. Schlegel declares that he has no conflict of interest.

Figures

Fig. 1
Fig. 1
Overall survival after blinatumomab treatment in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia. a Kaplan–Meier analysis of overall survival after initiation of blinatumomab treatment, according to the use of alloHSCT before blinatumomab, among all patients who received the recommended dosage. b Simon-Makuch analyses of overall survival after initiation of blinatumomab treatment, using a 1.5-month (45-day) landmark, according to use of alloHSCT after blinatumomab. c Simon-Makuch analyses of overall survival after initiation of blinatumomab treatment, using a 3-month (85-day) landmark, according to use of alloHSCT after blinatumomab in the subset of patients with CR within the first two cycles. d Overall survival by achievement of MRD response after blinatumomab treatment. MRD was not assessed for one patient in hematological CR. alloHSCT allogeneic hematopoietic stem-cell transplantation, CR complete remission, MRD minimal residual disease

Similar articles

See all similar articles

Cited by 6 articles

See all "Cited by" articles

References

    1. Ward E, DeSantis C, Robbins A, Kohler B, Jemal A. Childhood and adolescent cancer statistics, 2014. Ca. Cancer J. Clin. 2014;64:83–103. doi: 10.3322/caac.21219. - DOI - PubMed
    1. Ko RH, et al. Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium Study. J. Clin. Oncol. 2010;28:648–654. doi: 10.1200/JCO.2009.22.2950. - DOI - PMC - PubMed
    1. von Stackelberg A, et al. Outcome of children and adolescents with relapsed acute lymphoblastic leukaemia and non-response to salvage protocol therapy: a retrospective analysis of the ALL-REZ BFM Study Group. Eur. J. Cancer. 2011;47:90–97. doi: 10.1016/j.ejca.2010.09.020. - DOI - PubMed
    1. von Stackelberg A, et al. Phase I/phase II study of blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. J. Clin. Oncol. 2016;34:4381–4389. doi: 10.1200/JCO.2016.67.3301. - DOI - PubMed
    1. Chessells JM, et al. Long-term follow-up of relapsed childhood acute lymphoblastic leukaemia. Br. J. Haematol. 2003;123:396–405. doi: 10.1046/j.1365-2141.2003.04584.x. - DOI - PubMed

Publication types

MeSH terms

Substances

Feedback